BJUI Mini Reviews - Adjuvant Therapy of Renal Cell Carcinoma: Patient Selection and Therapeutic Options
Thursday, 01 September 2005
Furthermore, significant achievements in the
basic sciences have led to a greater knowledge of the underlying molecular genetics of
RCC, which hold promise for increased
sophistication in attempts to individualise
patient prognostication and future treatment
strategies.
Login to read more...
|
Percutaneous Radiofrequency Ablation Of Renal Masses Results At A 2-Year Mean Follow-Up
Wednesday, 31 August 2005
BERKELEY, CA (UroToday Inc.) - In this series of 49 patients with less than 4 cm renal tumors, all were treated with PERCUTANEOUS CT guided radiofrequency (RF) ablation, with 91% being done under conscious sedation, and 84% discharged as outpatients.
read more
|
The Effect Of Obesity In The Incidence Of Prostate, Bladder, And Renal Cancer In Men
Friday, 19 August 2005
BERKELEY, CA (UroToday Inc.) - Obesity has been associated with an increased risk of prostate and renal cancer. The majority of these epidemiological studies have been performed in Europe and in the United States.
read more
|
RF Ablation Promising Against Small Renal Tumors
Thursday, 18 August 2005
NEW YORK (Reuters Health) - Percutaneous radiofrequency (RF) ablation guided by computerized tomography appears to be an effective means of dealing with small renal tumors, researchers report in the August issue of the Journal of
Urology.
read more
|
Pfizer Submits Application For Sutent To FDA
Thursday, 11 August 2005
NEW YORK, August 10 -- Pfizer Inc said today that it has submitted a New Drug Application for its cancer medicine SU11248 (sunitinib malate), known as Sutent, to the U.S. Food and Drug Administration.
read more
|
MR Guided Cryoablation Promising Against Renal Tumors
Monday, 08 August 2005
NEW YORK (Reuters Health) - The results of a small study suggest that MR imaging-guided percutaneous cryotherapy is an effective means of treating patients with small renal tumors, researchers report in the August issue of Radiology.
read more
|
Surgical Outcomes For Isolated Renal Fossa Recurrence Following
Wednesday, 03 August 2005
BERKELEY, CA (UroToday Inc.) - Efficacious treatment of renal cell carcinoma is primarily surgical. Some patients recur only in the renal fossa.
read more
|
Long-Term Follow-up of Patients with Renal Cell Carcinoma Treated with Radio-Frequency Ablation with Curative Intent
Tuesday, 26 July 2005
BERKELEY, CA (UroToday Inc.) - Nephron sparing management of solid renal tumors has gained widespread acceptance over the past decade.
read more
|
A Molecular Classification of Papillary Renal Cell Carcinoma
Monday, 25 July 2005
Despite the moderate incidence of papillary renal cell
carcinoma (PRCC), there is a disproportionately limited
understanding of its underlying genetic programs.
read more
|
Impact Of Intraoperative Heparin On Laparoscopic Donor Nephrectomy
Thursday, 21 July 2005
BERKELEY, CA (UroToday Inc.) - The use of heparin during live donor nephrectomy remains controversial.
read more
|
Saline Cooling May Protect Kidney In RF Tumor Ablation
Monday, 18 July 2005
NEW YORK (Reuters Health) - Continuous irrigation of the ureter and renal pelvis with ice-cold saline may protect the renal collecting system from thermal injury during radiofrequency ablation (RFA) of central tumors, according to findings of animal studies in the July issue of the Journal of Urology.
read more
|
Younger Patients with Renal Cancers have Favorable Histology and Lower Stage Tumors
Friday, 15 July 2005
BERKELEY, CA (UroToday Inc.) - Patients age 20-40 years account for 3.5%-7.3% of presenting renal cell carcinomas (RCC). Historically, there has been the suggestion that outcomes for these patients is worse.
read more
|
Bayer and Onyx Complete Filing of New Drug Application
Wednesday, 13 July 2005
West Haven, CT and Emeryville, CA, July 11, 2005 -- Bayer Pharmaceuticals Corporation (NYSE:
BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the companies have
completed the submission of a New Drug Application (NDA) with the U.S. Food and Drug
Administration (FDA) for sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma
(RCC), or kidney cancer.
read more
|
Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006) for Individuals with Advanced Renal Cell Carcinoma
Wednesday, 13 July 2005
West Haven, CT and Emeryville, CA - May 14, 2005 - Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the availability of sorafenib (BAY 43-9006) through a treatment protocol for eligible individuals with advanced renal cell carcinoma (RCC), or kidney cancer.
read more
|
Validation of the 2002 American Joint Committee on Cancer Primary Tumor
Tuesday, 12 July 2005
BERKELEY, CA (UroToday Inc.) - In 2002 the American Joint Committee on Cancer (AJCC) primary tumor staging for renal cell carcinoma (RCC) changed.
read more
|
Radiofrequency Ablation Effective for Small Renal Tumors
Monday, 27 June 2005
NEW YORK (Reuters Health) - Temperature-based radiofrequency (RF) ablation is a reasonable nephron-sparing approach for treating select patients with small renal tumors, according to a report by US researchers.
read more
|
Laparoscopic Cryoablation for Renal Tumors: 3-Year Data
Wednesday, 15 June 2005
BERKELEY, CA (UroToday Inc.) - While the use of minimally invasive strategies renal mass ablation is rapidly expanding, few studies have evaluated its long-term efficacy.
read more
|
Positive Correlation Found Between Pathologic Findings in Renal Cell Carcinoma and Lewis Blood Group Expression
Tuesday, 14 June 2005
BERKELEY, CA (UroToday Inc.) - The interaction between tumor cells and endothelium plays a major role in cancer invasion and metastasis.
read more
|
The Utility of a Screening Renal Ultrasound in a High-Risk Population Reviewed
Monday, 13 June 2005
BERKELEY, CA (UroToday Inc.) - In the US alone, over 35,000 new patients are estimated to acquire diagnosis of renal cell carcinoma (RCCa) in 2004, and approximately 40% will die from the disease.
read more
|
Carbonic Anhydrase IX(CAIX) Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Friday, 10 June 2005
BERKELEY, CA (UroToday Inc.) - The presence of clear cell histology, pulmonary-only metastasis, and a favorable performance status subjectively predict a patient's response to IL-2 therapy in metastatic renal cancer.
read more
|
Intact Specimen Extraction After Laparoscopic Nephrectomy Identifies Patients at Higher Risk For Recurrence
Monday, 06 June 2005
BERKELEY, CA (UroToday Inc.) - Since the initial report by Clayman in 1992, laparoscopic nephrectomy has emerged as a standard approach for the management of small to medium sized localized renal masses.
read more
|
BJUI Mini Reviews - What’s New in the Treatment of Metastatic Kidney Cancer?
Wednesday, 01 June 2005
Factors such as
age, comorbidities and heterogeneous
histology can complicate the decision of
whether or not to treat aggressively or to
pursue a supportive, symptom-directed
approach
Login to read more...
|
BJUI Mini Reviews - The Molecular Basis of Cryosurgery
Wednesday, 01 June 2005
This article reviews the
cryobiological basis of cryosurgery and defines
the technical practices that should increase
the efficacy of the freezing techniques.
Login to read more...
|
Extensive Lymphadenectomy Fails to Provide Cancer-Specific Survival Advantage in Renal Cell Carcinoma
Sunday, 22 May 2005
BERKELEY, CA (UroToday Inc.) - Renal cell carcinoma (RCCa) accounts for 3% of cancers in the United States, with an estimated 31,900 cases and 11,900 deaths occurring in 2003.
read more
|
Sorafenib Slows Disease Progression in Kidney Cancer
Wednesday, 18 May 2005
ORLANDO (Reuters Health) - The dual-action kinase inhibitor sorafenib lengthens progression-free survival in patients with metastatic renal cell carcinoma (RCC), according to preliminary results of a phase III clinical trial reported this week at the American Society for Clinical Oncology conference.
read more
|
Multi-Target Drug Shows Promise in Advanced Refractory Kidney Cancer
Tuesday, 17 May 2005
ORLANDO (Reuters Health) - AG-013736, an experimental multi-action tyrosine kinase inhibitor displays significant antitumor activity in patients with cytokine-refractory advanced kidney cancer, according to the results of a phase II trial data presented Friday at the 41st annual meeting of the American Society of Clinical Oncology.
read more
|
Improved Hemostasis During Laparoscopic Partial Nephrectomy Using Gelatin Matrix Thrombin Sealant
Thursday, 05 May 2005
BERKELEY, CA (UroToday Inc.) - This stuff really works! While the naysayer would counter by stating this was a retrospective nonrandomized study and the improvement in decreased hemorrhage was due to the investigators increased experience, the counter argument would be that by 225 cases, the learning curve was presumably fairly well exhausted.
read more
|
BJUI Mini Reviews - Renal Haemangiopericytoma: The Characteristics of a Rare Tumour
Sunday, 01 May 2005
This review examines haemangiopericytoma (HPC),an unusual perivascular tumour
known to pathologists for more than 60 years and classified as a soft-tissue vascular tumour featuring the uncontrolled proliferation of pericytes.
Login to read more...
|
BJUI Mini Reviews - The Bosniak Classification of Renal Cystic Masses
Sunday, 01 May 2005
This review draws
together the available evidence on the use of
this classification and assesses alternative
techniques for evaluating complex renal cysts.
Login to read more...
|
All Patients in Bayer Cancer Trial to Get Active Drug
Tuesday, 19 April 2005
FRANKFURT (Reuters) - German drugs and chemicals group Bayer and partner Onyx Pharmaceuticals have recommended all patients in a phase III trial on their sorafenib drug for kidney cancer get access to the medicine.
read more
|
In Randomized Study of Patients with Localized Cancer and DVT, Low Molecular Weight Heparin found to offer Survival Advantage over Coumarin Derivatives
Friday, 15 April 2005
BERKELEY, CA (UroToday Inc.) - Without question, patients with cancer at a higher risk for thromboembolic events. Until very recently, the decision to place a patient with deep vein thrombosis (DVT) on coumarin or low molecular weight heparin was largely based on drug cost or patient convenience.
read more
|
Cryoablation Provides Effect Palliation for Bone Metastasis
Wednesday, 06 April 2005
NEW ORLEANS (Reuters Health) - In a series of 13 patients treated with cryoablation for palliation of pain from bone metastasis, more that half achieved total pain relief, according to results reported here this weekend at the 30th Annual Scientific Meeting of the Society of Interventional Radiology.
read more
|
Nephron Sparing and Simple Nephrectomy for the Treatment of Unilateral, Localized Wilms Tumor
Thursday, 10 March 2005
BERKELEY, CA (UroToday Inc.) - Success in treating Wilms tumor (WT) is based upon multimodal treatment, with surgery a central contributor to the outcomes.
read more
|
Prognostic Factors for Survival in Patients with Metastatic Renal Cell Carcinoma Reviewed
Monday, 07 March 2005
BERKELEY, CA (UroToday Inc.) - Approximately 30,000 new cases of renal cell carcinoma (RCC) are diagnosed in the United States each year.
read more
|
Prospective Randomized Comparison of Transperitoneal versus Retroperitoneal Laparoscopic Radical Nephrectomy
Tuesday, 08 February 2005
BERKELEY, CA (UroToday Inc.) - This long-awaited article has finally laid to rest the dilemma of which is better for the patient, the transperitoneal or the retroperitoneal laparoscopic radical nephrectomy.
read more
|
Kidney Recipients at Higher Risk of De Novo Renal Cell Cancer in Native Kidneys
Wednesday, 02 February 2005
NEW YORK (Reuters Health) - Kidney transplant recipients appear to have an increased risk of de novo renal cell carcinoma in their native kidneys, according to a report in the January 15th issue of Cancer.
read more
|
BJUI Mini Reviews - Conventional and Alternative Methods for Providing Analgesia in Renal Colic
Tuesday, 01 February 2005
This article reviews currently available analgesics and
summarize possible alternatives for this
condition.
Login to read more...
|
High-Dose IL-2 Still Preferred Therapy for Metastatic Renal Carcinoma
Monday, 31 January 2005
NEW YORK (Reuters Health) - Despite its considerable toxicity, high-dose interleukin-2 (IL-2) remains the favored therapy for many patients with metastatic renal cell cancer, according to findings from a phase III trial. For certain subgroups, however, a less toxic regimen involving subcutaneous IL-2 plus interferon may be a suitable alternative.
read more
|
Laparscopic Nephroureterectomy: What is The Preferred Approach to the Bladder Cuff?
Friday, 28 January 2005
BERKELEY, CA (UroToday Inc.) - Laparoscopic approaches provide significant quality of life advantages to the patient requiring a nephroureterectomy for upper tract urothelial carcinoma.
read more
|
Prospective, Randomized Controlled Study: Transperitoneal Laparoscopic versus Retroperitoneal Radical Nephrectomy
Thursday, 13 January 2005
BERKELEY, CA (UroToday Inc.) - Contrary to the authors' claims of primacy, this is the second study of this nature, the first having been presented by Gill and colleagues at the 2002 AUA with a larger number of patients.
read more
|
Autopsy Prevalence of Renal Cell Cancer
Tuesday, 11 January 2005
BERKELEY, CA (UroToday Inc.) - Renal cell cancer (RCC) is more frequently identified in the present era, possibly due to increased abdominal imaging for a variety of both urologic and non-urologic indications.
read more
|
Renal Parenchymal Imaging for Hematuria Adds to the Detection of Renal Lesions, but Results in Little Additional Intervention
Tuesday, 11 January 2005
BERKELEY, CA (UroToday Inc.) - Hematuria, whether macroscopic or microscopic, requires evaluation. The standard in the United States has been an upper tract study, usually an IVP, and a cystoscopy.
read more
|
Elevated BMI Increases Risk of Renal Cell Carcinoma
Tuesday, 04 January 2005
NEW YORK (Reuters Health) - The risk of renal cell carcinoma (RCC) is directly related to body mass index (BMI) and to the increase in BMI since age 20, according to the findings of two European studies reported in the American Journal of Epidemiology for December 15th.
read more
|
Systematic Review Links Hospital or Surgeon Volumes with Outcomes of Urologic Oncology Procedures
Tuesday, 21 December 2004
BERKELEY, CA (UroToday Inc.) - It seems intuitive that higher volume centers or surgeons might obtain better outcomes for complex surgical procedures.
read more
|
Obesity Does Not Alter Prognosis in Kidney Cancer Patients
Wednesday, 15 December 2004
BERKELEY, CA (UroToday Inc.) - The reported impact of body mass index (BMI) on the incidence and prognosis of patients with renal cell carcinoma (RCC) has varied in existing literature.
read more
|
Wilms' Tumor in Adults: Results of the Society of Pediatric Oncology 93-01/Society for Pediatric Oncology and Hematology Study
Monday, 06 December 2004
BERKELEY, CA (UroToday Inc.) - While Wilms tumor is the most common renal tumor in children, it is rare after the age of 16.
read more
|
Renal Mass with Nonrenal Malignancy May Not Need Biopsy
Friday, 03 December 2004
NEW YORK (Reuters Health) - In patients with renal masses identified during follow-up of localized nonrenal malignancy, biopsy may not always be necessary, report investigators at The University of Texas M. D. Anderson Cancer Center in Houston.
read more
|
Outcomes Following Non-operative Management of Renal Masses
Wednesday, 24 November 2004
BERKELEY, CA (UroToday Inc.) - Due to incidental discovery of renal masses, urologists are now often confronted with management of these tumors in elderly or other surgically unsuitable patients.
read more
|
Elderly Patients Underrepresented in Trials of New Cancer Drugs
Wednesday, 17 November 2004
NEW YORK (Reuters Health) - New research indicates that cancer patients over 65 years of age are underrepresented in registration trials of new cancer agents.
read more
|
Laparoscopic Partial Nephrectomy: Effect of Warm Ischemia on Serum Creatinine.
Wednesday, 03 November 2004
BERKELEY, CA (UroToday Inc.) - How much warm ischemia time does it take to permanently damage the human kidney?
read more
|
Renal Cancer 
